2020 Drug Formulary

Total Page:16

File Type:pdf, Size:1020Kb

2020 Drug Formulary 2020 Drug Formulary CHPW_RX_311_08_2020_Medicaid_Formulary_SEP COMMUNITY HEALTH PLAN of WASHINGTON 2020 DRUG FORMULARY The Community Health Plan of Washington (CHPW) drug formulary is developed by a Pharmacy and Therapeutics Committee. For medications included in the Apple Health Preferred Drug List, formulary status and coverage criteria are developed and approved by the Washington State Authority (HCA) Pharmacy and Therapeutics Committee before adoption by CHPW. All other medications’ formulary status and coverage criteria are developed and approved by the CHPW Pharmacy and Therapeutics Committee. The formulary is searchable on the website at http:// chpw.org/for-members/pharmacy. For more information on the Apple Health Preferred Drug List, please visit: https://www.hca.wa.gov/billers-providers-partners/programs-and-services/apple- health-preferred-drug-list-pdl. The Formulary may change at any time. For updates regarding periodic changes to the Formulary and other pharmaceutical management programs please check our website at www.chpw.org/for-members/pharmacy. This Drug Formulary is intended for use by our providers and pharmacies and applies only to medications prescribed to our members and dispensed by participating network pharmacies. The Formulary does not apply to inpatient medications. Generic Drug Policy Community Health Plan of Washington utilizes a mandatory generic policy. This means that unless specified, the brand product won’t be covered without adequate trial and documented failure of the formulary generic product. Only when generic substitution conflicts with state regulations or restrictions, the pharmacist must gain approval from the prescriber to use the generic equivalent. OTC Medication Policy Some Over-The-Counter (OTC) products are covered with a written prescription. If a prescription product is available in the identical strength, dosage form, and active ingredient(s) as an OTC product, the prescription product will not be covered. In these instances, providers and pharmacists should refer members to the OTC equivalent product. If the member or provider insists on the prescription equivalent product, the member must pay the entire cost of the prescription. Age Restrictions Age restrictions apply to selected drugs. These drugs are covered without prior authorization for specific age ranges but otherwise require prior authorization. Mental health medications outside of HCA mandated age/dose limits Tretinoin—covered for members under 30 years old Opioid prescriptions outside of HCA mandated age/dose limits 1 Second Opinion Network (SON) Community Health Plan of Washington has adopted Washington State Health Care Authority medication review thresholds for certain psychotropic medications for children under 18 years old. Clients currently receiving medications outside of these medication review thresholds will be allowed to continue, regardless of previous payer (whether HCA FFS, the plan themselves, or a previous payer prior to the client becoming a Medicaid enrollee). Clients being prescribed medications for the first time, or receiving prescriptions for dose escalations which exceed thresholds, will have those prescriptions denied by the managed care plans, and referred to HCA for initiation of the second opinion review process. After completion of the second opinion review, the managed care plan will receive a copy of the SON written recommendation, and approve or deny future prescriptions accordingly. Exception Request The health care professionals consulted in the development of this Formulary attempted to include medications for all therapeutic needs. Providers are expected to comply with the Drug Formulary when prescribing medications for plan members. If a patient requires a medication that is not covered, the provider may request an exception to allow payment for the non-covered medication. It is anticipated that such exceptions will be rare, and that most of the time, providers should be able to find a Formulary medication for the vast majority of therapeutic needs. However, if providers desire a non-covered product for members, they must call or submit a request explaining the necessity, past therapeutic failures and patient identification (name, address and Community Health Plan of Washington member number). Prior Authorization To promote the most appropriate utilization, selected high-risk or high-cost medications require prior authorization to be eligible for coverage. Prior authorization criteria have been developed using current, published, peer-reviewed, medical literature, as well as input from local providers. The prior authorization criteria are approved by the P&T Committee. The Formulary medications that require prior authorization are identified by a “PA” following their name. Most authorizations are good for one year; after that, the drugs listed here will need to be reauthorized. Drugs may be added or deleted from this list as deemed necessary. Prior Authorization Requests: Non Formulary and Prior Authorization requests must be directed to: Express Scripts Attn: Prior Authorization Mail Stop B401-03 8640 Evans Road St. Louis, MO 63134 Phone: 844-605-8168 Fax: 877-251-5896 Electronic Prior Authorization requests can be submitted through: www.express-scripts.com/PA 2 Step Therapy Step-­­therapy promotes appropriate utilization of first line drugs and/or therapeutic categories. Step-­­ therapy requires that participants receive one or more first-­­line drug(s), as defined by program criteria, before prescriptions are covered for second-­­line drugs. All step-­­therapy programs are supported by prior authorization criteria to determine coverage in the event that a participant does not meet the automated, on-­­line step-­­therapy criteria and coverage of a second line product is medically necessary. Benefit Exclusions Drugs in the following categories are not available as benefits of the plan: Non-­­FDA approved drug products Medications will be eligible for coverage only if they are FDA-­­ approved prescription medications used for non-­­experimental indications. Experimental and Investigational (E & I) drugs These are drugs that do not have FDA-­­ approved indication(s) for use, or other indications that are considered effective based on published scientific evidence. Compounded drugs with non-­­FDA approved ingredients (e.g. Estriol used in Bi-­­Est and Tri-­­Est) Samples Members started on samples of a non-­­formulary drug are not guaranteed coverage for that drug. Drugs for weight loss or appetite suppression (e.g. Xenical) Drugs for impotence or sexual dysfunction (e.g.Viagra) Drugs to treat cosmetic issues (e.g.Rogaine) Infertility drugs Prescription drugs that are equivalent to OTC medications or with an OTC add on (Some OTC medications are covered for Apple Health.) Benefit Information: Retail Pharmacy A 30 day supply is allowed at all network retail pharmacies and a 90-day supply of select generic maintenance medications at select pharmacies. Mail Order Pharmacy Contact Walmart pharmacy at 1-800-273-3455 to get your medications sent to you. Copay Determinations There is no copay or deductible for formulary products for Apple Health. OTC products: Only certain OTC products are covered for Community Health Plan of Washington members as determined by the Apple Health Preferred Drug List. 3 Formulary Legend: Generic drugs are listed in lower case BRAND drugs are listed in UPPER case Tier 1: Preferred. No limits. Tier 2: Preferred. With limits. Tier 3: Non Preferred. Tier 4: Medical Benefit. PA: Prior Authorization. The Plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval before you fill your prescriptions. If you don’t get approval, we may not cover the drug. QL: Quantity Limit. For certain drugs, there are limits on the amount of the drug that we will cover. ST: Step Therapy. In some cases, the Plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B. 4 COMMUNITY HEALTH PLAN OF WASHINGTON FORMULARIO DE MEDICAMENTOS 2020 El Formulario de medicamentos de Community Health Plan of Washington (CHPW) es desarrollado por el Comité de Farmacia y Terapéutica (P&T). Para los medicamentos incluidos en la Lista de medicamentos preferidos de Apple Health, el Comité de Farmacia y Terapéutica de la Autoridad de Atención Médica de Washington (HCA) desarrolla y aprueba el estado del formulario y el criterio de cobertura antes de que CHPW los adopte. El resto de los criterios de cobertura y de los estados de los formularios de medicamentos son desarrollados y aprobados por el Comité de Farmacia y Terapéutica de CHPW. El formulario se puede consultar en el sitio web http://chpw.org/for-members/pharmacy. Para obtener más información sobre la Lista de medicamentos preferidos de Apple Health, visite https://www.hca.wa.gov/billers-providers-partners/programs-and-services/apple-health- preferred-drug-list-pdl. El Formulario puede cambiar en cualquier momento. Para acceder a los cambios periódicos en el Formulario y otros programas de administración de productos farmacéuticos, visite nuestro sitio web en www.chpw.org/for-members/pharmacy. Este Formulario de medicamentos está destinado a nuestros proveedores y farmacias, y se aplica solo a los medicamentos
Recommended publications
  • Medical Cannabis Q&A
    Medical Cannabis Q&A 1. What is medical cannabis? The term “medical cannabis” is used to describe products derived from the whole cannabis plant or its extracts containing a variety of active cannabinoids and terpenes, which patients take for medical reasons, after interacting with and obtaining authorization from their health care practitioner. 2. What are the main active ingredients? The chemical ingredients of cannabis are called cannabinoids. The two main therapeutic ones are: THC:CBD a. Tetrahydrocannabinol (THC) is a partial agonist of CB1 and CB2 receptors. It is psychoactive and produces the euphoric effect. Each cannabis product will contain THC and CBD, however b. Cannabidiol (CBD) has a weak affinity for CB1 and CB2 receptors and appears the THC: CBD ratio will differ to exert its activity by enhancing the positive effects of the body’s endogenous depending on the product. cannabinoids. 3. Why do patients take it? Medical cannabis may be used to alleviate symptoms for a variety of conditions. It has most commonly been used in neuropathic pain and other chronic pain conditions. There is limited, but developing clinical evidence surrounding its safety and efficacy, and it does not currently have an approved Health Canada indication. 4. How do patients take it? Cannabis can be smoked, vaporized, taken orally, sublingually, topically or rectally. Different routes of administration will result in different pharmacokinetic and pharmacodynamic properties of the drug. 5. Is it possible to develop dependence on medical cannabis? Yes, abrupt discontinuation after long-term use may result in withdrawal symptoms. Additionally, chronic use may result in psychological dependence.
    [Show full text]
  • 2019 Ministerial Declaration
    COMMISSION ON NARCOTIC DRUGS VIENNA IMPLEMENTATION OF ALL INTERNATIONAL DRUG POLICY COMMITMENTS Follow-up to the 2019 Ministerial Declaration “Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem” UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Commission on Narcotic Drugs IMPLEMENTATION OF ALL INTERNATIONAL DRUG POLICY COMMITMENTS Follow-up to the 2019 Ministerial Declaration “Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem” UNITED NATIONS Vienna, 2019 © United Nations, July 2019. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Contents 1. Ministerial Declaration on Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem ...............................1 2. Outcome document of the thirtieth special session of the General Assembly, entitled “Our joint commitment to effectively addressing and countering the world drug problem” ..................................................9 3. Joint Ministerial Statement of the 2014 High-Level Review by the Commission on Narcotic Drugs of the Implementation by Member States of the Political Declaration and Plan of Action on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem ...............................35 4.
    [Show full text]
  • Public Safety Aspects of the Heroin Abuse Epidemic
    A brief from June 2015 Public Safety Aspects of the Heroin Abuse Epidemic Overview Policymakers at all levels of government are attempting to address a nationwide increase in heroin abuse.1 Use of the drug has tripled over the past decade, paralleling widespread misuse of prescription opioids, and overdose deaths have increased nearly threefold in the past seven years. Available research suggests that the most effective response to the growth in heroin abuse is a combination of law enforcement to curtail trafficking and limit the emergence of new markets; alternative sentencing to divert nonviolent drug offenders from costly incarceration; treatment to reduce dependency and recidivism; and prevention efforts that can help identify individuals at high risk for addiction. These strategies are most effective when tailored to the specific nature of the heroin problem in a given community. Research further suggests that increasing criminal penalties for heroin-related offenses is unlikely to reverse the growth in heroin use and tends to have a poor return on investment. Figure 1 Heroin Seizures Increased Substantially Starting in 2007 Authorities cite expansion of Mexican production and trafficking 6,000 5,691 kg 5,000 4,000 3,000 2,486 kg 2,000 Heroin seizures (kilograms) 1,000 0 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 Source: Office of National Drug Control Policy, 2014 National Drug Control Strategy, “Data Supplement, Table 71,” https://www. whitehouse.gov/sites/default/files/ondcp/policy-and-research/ndcs_data_supplement_2014.pdf © 2015 The Pew Charitable Trusts Heroin supply on the rise What Is Heroin? Between 2007 and 2013, heroin seizures by federal, state, and local law Heroin is a highly enforcement increased 289 percent.2 (See Figure 1.) U.S.
    [Show full text]
  • Try These Olive Oil & Balsamic Vinegar Combinations
    Try these Olive Oil & Balsamic Vinegar Combinations Olive Oil + Balsamic (Swirl to mix) Lemon + Honey - Ginger , Oregano or Raspberry Lemon + Comice Pear, Lavender or Passion Fruit Baklouti Green Chili + Grapefruit, Peach or Honey Ginger Lemon + Cascadian Wild Raspberry or Cranberry-Pear Baklouti Green Chili + Pineapple or Pomegranate-Quince Milanese Gremolata + Grapefruit or Neapolitan Herb Basil + Strawberry, Comice Pear or Black Mission Fig Milanese Gremolata + Lemongrass-Mint or Oregano Basil + Blackberry-Ginger, Vanilla, Lavender or Blueberry Milanese Gremolata + Sicilian Lemon or Black Mission Fig Blood Orange + Cinnamon-Pear or Dark Chocolate Wild Mushroom/Sage + Sicilian Lemon or Blenheim Apricot Blood Orange + Espresso, Maple, Blueberry or Tangerine Wild Mushroom/Sage + Cranberry-Pear or Black Cherry Blood Orange + Lavender, Peach or Black Mission Fig Persian Lime + Blackberry-Ginger or Cinnamon-Pear Butter + Maple, Lemon, Coconut or Dark Chocolate Persian Lime + Honey-Ginger, Key Lime, Lavender or Vanilla Cayenne Chili + Mango, Peach or Cara-Cara Orange/Vanilla Persian Lime + Red Apple, Coconut or Gravenstein Apple Cayenne Chili + Coconut, Cascadian Wild Rasp. or Pineapple Rosemary + Sicilian Lemon, Comice Pear or Pomegranate Chaabani Chili + Neapolitan Herb or Sicilian Lemon Rosemary + Neapolitan Herb, Cranberry-Pear or Blenheim Apricot Chaabani Chili + Comice Pear or Gravenstein Apple Rosemary + Blackberry-Ginger, Mango or Black Cherry Chipotle + Dark Chocolate, Jalapeño or Strawberry Rosemary + Cascadian Wild Raspberry Chipotle
    [Show full text]
  • Diversion and Illicit Supply of Medicines
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Medicines Working Group Secretary: Mohammed Ali 1st Floor (NE), Peel Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 0459 Email: [email protected] Rt Hon. Amber Rudd MP Home Office 2 Marsham Street London SW1P 4DF Rt Hon. Jeremy Hunt MP Department of Health Richmond House 79 Whitehall London SW1A 2NS 15 December 2016 Dear Home Secretary and Secretary of State for Health ACMD report on Diversion and Illicit Supply of Medicines The Advisory Council on the Misuse of Drugs (ACMD) is pleased to enclose its report on Diversion and Illicit Supply of Medicines (referred to as ‘DISM’) for your consideration. This report is in response to the Home Office’s commissioning letter of September 2013, in which the then Home Secretary requested the ACMD to explore the potential for medical and social harms arising from the illicit supply of medicines – predominantly controlled medicines. We are grateful to the ACMD’s stakeholders, who provided presentations at the evidence gathering days as well as helpful written submissions (these are included in a separate attachment, alongside the main report on the ACMD website). This report sets out to: • explore the extent of DISM in the UK, to find out which drugs are being diverted; • evaluate the extent of the medical and social harms of such diversion; and • assess whether DISM displaces or replaces the use of known recreational drugs of abuse, such as heroin. In recent years, DISM has become of increasing public concern across the globe, although the hard evidence for this constituting a major problem other than in the United States is hard to find.
    [Show full text]
  • Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C
    NEW JERSEY CANNABIS REGULATORY COMMISSION Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C. 17:30 Adopted: August 19, 2021 by New Jersey Cannabis Regulatory Commission, Dianna Houenou, Chair. Filed: August 19, 2021 Authority: N.J.S.A. 24:6I-31 et seq. Effective Date: August 19, 2021 Expiration Date: August 19, 2022 This rule may be viewed or downloaded from the Commission’s website at nj.gov/cannabis. These rules are adopted pursuant to N.J.S.A. 24:6I-34(d)1a of the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, N.J.S.A. 24:6I- 31 et seq., and became effective upon acceptance for filing by the Office of Administrative Law. The specially adopted new rules shall be effective for a period not to exceed one year from the date of filing of the new rules, that is, until August 19, 2022. The Commission has provided this special adoption to the Attorney General, State Treasurer, Commissioner of Health, and Commissioner of Banking and Insurance for a consultation period, after which the Commission anticipates filing a proposal to readopt these rules with amendments reflecting the results of that consultation. In accordance with N.J.S.A. 24:6I-34(d)1b the rules, as readopted, will become effective upon acceptance for filing by the Office of Administrative Law if filed on or before the expiration date of the rules published herein. The adopted amendments will be effective upon publication in the New Jersey Register. Federal Standards Analysis The Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act obliges the Cannabis Regulatory Commission to promulgate rules necessary or proper to enable it to carry out the Commission’s duties, functions, and powers with respect to overseeing the development, regulation, and enforcement of activities associated with the personal use of cannabis pursuant to P.L.2021, c.16.
    [Show full text]
  • Deanxit SPC.Pdf
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Deanxit film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Flupentixol 0.5 mg (as 0.584 mg flupentixol dihydrochloride) Melitracen 10 mg (as 11.25 mg melitracen hydrochloride) Excipients with known effect: Lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets. Round, biconvex, cyclamen, film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Anxiety Depression Asthenia. Neurasthenia. Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts. 4.2 Posology and method of administration Posology Adults Usually 2 tablets daily: morning and noon. In severe cases the morning dose may be increased to 2 tablets. The maximum dose is 4 tablets daily. Older people (> 65 years) 1 tablet in the morning. In severe cases 1 tablet in the morning and 1 at noon. Maintenance dose: Usually 1 tablet in the morning. SPC Portrait-REG_00051968 20v038 Page 1 of 10 In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended. Paediatric population Children and adolescents (<18 years) Deanxit is not recommended for use in children and adolescents due to lack of data on safety and efficacy. Reduced renal function Deanxit can be given in the recommended doses. Reduced liver function Deanxit can be given in the recommended doses. Method of administration The tablets are swallowed with water. 4.3 Contraindications Hypersensitivity to flupentixol and melitracen or to any of the excipients listed in section 6.1.
    [Show full text]
  • Alchemy V Gf
    SMOOTHIE BOWLS ALCHEMY V GF café SANDWICHES SALAD blueberry almond butter 10 V GF sub gluten free bread +2 acai, blueberries, banana, almond butter, almond milk topped with kale caesar 11 banana, coconut, granola, goji V bahn mi 9.5 baby kale, carrots, toasted berries mushroom walnut pate, carrot chickpeas, cashew caesar, cashew cilantro slaw, sriracha aioli, parm, hazelnuts › add smoked microgreens, farm bread salmon +5, avocado +1.5 VG egg sandwich 8.5 egg soufflé, havarti, zesty cashew cherry cheezcake 10 cream, arugula, focaccia › add acai, cherries, vanilla cashew cream, avocado +1.5, smoked salmon +5 almond milk, topped with granola, BEVERAGES almond butter, cranberry pecan V GF turkey bacon caesar 11.5 no-bake turkey, bacon, baby kale, carrot, cashew caesar dressing, ciabatta cold brew 3.5 iced oat smoked salmon club 11 smoked salmon, arugula, tomato, milk latte 5 chunky monkey 10 cucumber, red onion, carrot, lemon acai, banana, peanut butter, cacao, caper mayo, whole wheat tahini vietnamese 6 maple, almond milk, topped with cold brew, tahini, coconut milk peanut butter cacao no-bake, coconut, cacao nibs › add fresh V basil portobello 9.5 strawberries +1 roasted portobello, herbed cashew iced london fog 6 cream, arugula, roasted red pepper, earl grey, oat milk, blackberry jam red onion, ciabatta hot tea 3 jalapeño turkey 10 turkey, black bean spread, pepper superfood lattes 5 rainbow cookie monster 10 jack cheese, micro greens, tomato, choose hot (hemp milk) or banana, cashew butter, vanilla vegan farm bread iced (almond milk)
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • The Biden-Harris Administration's Statement of Drug Policy Priorities
    EXECUTIVE OFFICE OF THE PRESIDENT OFFICE OF NATIONAL DRUG CONTROL POLICY Washington, DC 20503 The Biden-Harris Administration’s Statement of Drug Policy Priorities for Year One The overdose and addiction crisis has taken a heartbreaking toll on far too many Americans and their families. Since 2015, overdose death numbers have risen 35 percent, reaching a historic high of 70,630 deaths in 2019.1 This is a greater rate of increase than for any other type of injury death in the United States.2 Though illicitly manufactured fentanyl and synthetic opioids other than methadone (SOOTM) have been the primary driver behind the increase, overdose deaths involving cocaine and other psychostimulants, like methamphetamine,3 have also risen in recent years, particularly in combination with SOOTM. New data suggest that COVID-19 has exacerbated the epidemic,4, 5 and increases in overdose mortality6 have underscored systemic inequities in our nation’s approach to criminal justice and prevention, treatment, and recovery. President Biden has made clear that addressing the overdose and addiction epidemic is an urgent priority for his administration. In March, the President signed into law the American Rescue Plan, which appropriated nearly $4 billion to enable the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration to expand access to vital behavioral health services. President Biden has also said that people should not be incarcerated for drug use but should be offered treatment instead. The President has also emphasized the need to eradicate racial, gender, and economic inequities that currently exist in the criminal justice system.
    [Show full text]
  • Rethinking America's Illegal Drug Policy
    NBER WORKING PAPER SERIES RETHINKING AMERICA'S ILLEGAL DRUG POLICY John J. Donohue III Benjamin Ewing David Peloquin Working Paper 16776 http://www.nber.org/papers/w16776 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 February 2011 The authors wish to thank Jonathan Caulkins, Phil Cook, Louis Kaplow, Rob MacCoun, Jeffrey Miron, Peter Reuter, and participants at two NBER conferences and the Harvard Law School Law and Economics workshop for valuable comments. We are also particularly grateful to Jeffrey Miron and Angela Dills for sharing their national time series data on drug prohibition enforcement and crime. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research. © 2011 by John J. Donohue III, Benjamin Ewing, and David Peloquin. All rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided that full credit, including © notice, is given to the source. Rethinking America's Illegal Drug Policy John J. Donohue III, Benjamin Ewing, and David Peloquin NBER Working Paper No. 16776 February 2011, Revised March 2011 JEL No. K0 ABSTRACT This paper provides a critical review of the empirical and theoretical literatures on illegal drug policy, including cross-country comparisons, in order to evaluate three drug policy regimes: criminalization, legalization and “depenalization.” Drawing on the experiences of various states, as well as countries such as Portugal and the Netherlands, the paper attempts to identify cost-minimizing policies for marijuana and cocaine by assessing the differing ways in which the various drug regimes would likely change the magnitude and composition of the social costs of each drug.
    [Show full text]
  • (A-9-THC) Content in Herbal Cannabis Over Time
    32 Current Drug Abuse Reviews, 2012, 5, 32-40 Increasing Delta-9-Tetrahydrocannabinol (-9-THC) Content in Herbal Cannabis Over Time: Systematic Review and Meta-Analysis Fidelia Cascini*,1, Carola Aiello2 and GianLuca Di Tanna3 1Istituto di Medicina Legale, Università Cattolica del S. Cuore, largo F. Vito, 1 00168 Roma, Italy 2Department of Informatics and Systemics, University ‘La Sapienza’, 00185 Rome, Italy 3Department of Public Health and Infectious Diseases, University "La Sapienza", 00185, Rome, Italy Abstract: Aim: The objective of this meta-analysis is to assess the data regarding changes in herbal cannabis potency over time (from 1970 to 2009). Methods: Systematic searches of 17 electronic scientific databases identified studies on this topic, within which 21 case series studies satisfied our inclusion criteria of reporting the mean tetrahydrocannabinol (THC) value per number of samples per year. No language, publication date, publication type or status restrictions were imposed. The study selection and data extraction processes were performed independently but uniformly by two authors, included screening, determination of eligibility and inclusion of the eligible studies in the systematic review, and a meta-analysis of the results on THC content in herbal cannabis samples. We considered papers and not monographic scientific publications, rejecting all studies that were not focused on the subject of this review. Results: Meta-analysis by year was performed on 21 studies containing 75 total mean THC observations from 1979 to 2009 using the random effects model. The results revealed much variability between studies. Further, there was a significant correlation between year and mean THC in herbal cannabis. The combined data indicated the correlation between year and mean THC in herbal cannabis, revealing a temporal trend of increasing potency (5% above the mean THC value in the Poisson regression analysis).
    [Show full text]